Elite Pharmaceuticals Q1 FY2027: Revenue Falls 19.5%, Material Weaknesses Disclosed

summarizeSummary

Elite Pharmaceuticals' Q1 FY2027 revenue fell 19.5% to $32.4 million, gross margin dropped to 42%, and the company disclosed material weaknesses in internal controls.

check_boxKey Events · Earnings and Guidance · ELTP

• Revenue Declines 19.5%

  Q1 FY2027 revenue was $32.4 million, down from $40.2 million in the prior-year quarter, driven by lower manufacturing fees and increased market competition.

• Gross Margin Compresses to 42%

  Gross profit fell 50% to $13.5 million as cost of manufacturing rose 45% while average net prices declined, particularly for Lisdexamfetamine.

• Material Weaknesses in Internal Controls

  Management identified material weaknesses including insufficient segregation of duties, lack of compensating controls, and ineffective disclosure controls and procedures as of June 30, 2026.

• Net Income Swings to Positive

  Net income was $5.9 million, compared to a net loss of $5.9 million in the prior-year quarter, aided by a $22.2 million favorable swing in warrant fair value adjustments.

auto_awesomeAnalysis · ELTP · Life Sciences

Elite Pharmaceuticals reported Q1 FY2027 revenue of $32.4 million, down 19.5% year-over-year, with net income of $5.9 million compared to a net loss of $5.9 million in the prior-year quarter. Gross margin compressed to 42% from 68% due to increased competition and lower net prices on key products like Lisdexamfetamine. More concerning, management disclosed material weaknesses in internal control over financial reporting, including insufficient segregation of duties and lack of compensating controls, and concluded that disclosure controls and procedures were not effective as of June 30, 2026. These control deficiencies raise the risk of financial misstatements and undermine confidence in reported figures.